FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 16 filers reported holding FATE THERAPEUTICS INC in Q4 2013. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2016 | $908,000 | +83.4% | 291,067 | 0.0% | 0.10% | +45.6% |
| Q2 2016 | $495,000 | -3.9% | 291,067 | +1.8% | 0.07% | -2.9% |
| Q1 2016 | $515,000 | -47.5% | 285,953 | -1.8% | 0.07% | -61.7% |
| Q4 2015 | $981,000 | -36.8% | 291,067 | 0.0% | 0.18% | -53.1% |
| Q3 2015 | $1,551,000 | -17.6% | 291,067 | 0.0% | 0.39% | -52.7% |
| Q2 2015 | $1,883,000 | +32.3% | 291,067 | 0.0% | 0.82% | -41.4% |
| Q1 2015 | $1,423,000 | -2.8% | 291,067 | 0.0% | 1.40% | +237.7% |
| Q4 2014 | $1,464,000 | -1.3% | 291,067 | +0.0% | 0.42% | -45.2% |
| Q3 2014 | $1,484,000 | -19.6% | 291,000 | -0.5% | 0.76% | -56.4% |
| Q2 2014 | $1,846,000 | -37.6% | 292,567 | -3.6% | 1.74% | +54.9% |
| Q1 2014 | $2,956,000 | +55.1% | 303,538 | 0.0% | 1.12% | -5.9% |
| Q4 2013 | $1,906,000 | – | 303,538 | – | 1.19% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARCH Venture Management, LLC | 2,073,190 | $26,599,000 | 26.59% |
| Polaris Venture Management Co. V, L.L.C. | 1,823,186 | $23,391,000 | 24.97% |
| Casdin Capital, LLC | 2,550,000 | $32,717,000 | 5.60% |
| Redmile Group, LLC | 10,359,666 | $132,915,000 | 5.34% |
| Aquilo Capital Management, LLC | 697,096 | $8,944,000 | 4.33% |
| Eversept Partners, LP | 165,000 | $2,116,950 | 1.15% |
| Artal Group S.A. | 2,150,000 | $27,585,000 | 1.02% |
| AlpInvest Partners B.V. | 26,925 | $345,000 | 0.99% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,654,865 | $21,232,000 | 0.85% |
| Lisanti Capital Growth, LLC | 142,760 | $1,832,000 | 0.74% |